Company Profile
Akebia Therapeutics Stock Price, News & Analysis
- Ticker:
- AKBA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.95 USD (-26.02%)
Close
Last updated: August 6, 2026
251M USD
Market cap
Why the stock is moving
Following the latest company update, “Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights”, AKBA closed down 26.0% at $0.9544 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Kidney-Disease Company
Akebia Therapeutics develops and commercializes medicines for people with kidney disease. Its portfolio combines an anemia franchise with clinical programs for rare and acute renal disorders.
Vafseo
Vafseo, or vadadustat, is an oral HIF prolyl-hydroxylase inhibitor for anemia due to chronic kidney disease in adults receiving dialysis. Akebia is conducting post-approval studies of alternative dosing and clinical outcomes.
Vafseo Evidence Program
The VOCAL Phase 3b study evaluates three-times-weekly Vafseo dosing, while the large Phase 4 VOICE study compares mortality and hospitalization outcomes with standard erythropoiesis-stimulating agents.
Praliciguat
Praliciguat is an oral soluble-guanylate-cyclase stimulator in Phase 2 testing for focal segmental glomerulosclerosis.
AKB-097
AKB-097 is preparing for a Phase 2 basket study in IgA nephropathy, lupus nephritis and C3 glomerulopathy.
AKB-9090
AKB-9090 is in Phase 1 development as a potential preventive treatment for cardiac-surgery-associated acute kidney injury.
Future catalysts
Initiation of a Phase 2 basket study of AKB-097 in the second half of 2026.
Topline Phase 3b VOCAL data in the fourth quarter of 2026.
Topline Phase 1 data for AKB-9090 in early 2027.
Initial Phase 2 data for AKB-097 in 2027.
Topline Phase 4 VOICE data in early 2027.
Recent news
- 01
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Source: Akebia Therapeutics
- 02
- 03
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
Source: Akebia Therapeutics
- 04
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Akebia Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Akebia Therapeutics (AKBA)?
Akebia Therapeutics (AKBA) most recently closed at 0.95 USD, a -26.02% move versus the previous session.
What is the market cap of Akebia Therapeutics (AKBA)?
Akebia Therapeutics currently has a market capitalization of 251M USD on BioPharmSignal.
What does Akebia Therapeutics do?
Kidney-Disease Company Akebia Therapeutics develops and commercializes medicines for people with kidney disease. Its portfolio combines an anemia franchise with clinical programs for rare and acute renal disorders. Vafseo Vafseo, or vadadustat, is an oral HIF prolyl-hydroxylase inhibitor for anemia due to chronic kidney disease in adults receiving dialysis....
On which exchange is AKBA stock listed?
Akebia Therapeutics (AKBA) is associated with NASDAQ, United States, Biopharma.
What is AKB-097?
Initiation of a Phase 2 basket study of AKB-097 in the second half of 2026.
Which conditions is Akebia Therapeutics targeting with AKB-097?
Initiation of a Phase 2 basket study of AKB-097 in the second half of 2026.
How does Akebia Therapeutics describe recent progress with AKB-097?
Initiation of a Phase 2 basket study of AKB-097 in the second half of 2026.
What is AKB-9090?
AKB-9090 AKB-9090 is in Phase 1 development as a potential preventive treatment for cardiac-surgery-associated acute kidney injury.